ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "metabolomics"

  • Abstract Number: 0044 • ACR Convergence 2023

    Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis

    Menghao Zhang1, Na Kang2, Xin Yu1, Wanli Liu2 and Wenjie Zheng1, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 2Beijing Key Lab for Immunological Research on Chronic Diseases, School of Life Sciences, Institute for Immunology, Tsinghua University, Beijing, China

    Background/Purpose: Behçet’s disease (BD) is a chronic vasculitis characterized by polymorphonuclear neutrophils (PMNs) hyperactivation with unknown etiology. The over-productions of neutrophil extracellular traps (NETs) and…
  • Abstract Number: 2149 • ACR Convergence 2023

    Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors

    Yuriko Yamamura1, Kieran Woolcock2, Valerie Corrigall3, Lara Ravanetti4, Jorge De Alba4, Roly Foulkes5, Paul Eggleton6 and Carl Goodyear2, 1School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Revolo Biotherapeutics, Tadworth, United Kingdom, 4Revolo Biotherapeutics, London, United Kingdom, 5Revolo Biotherapeutics, Slough, United Kingdom, 6Revolo Biotherapeutics, Exeter, United Kingdom

    Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…
  • Abstract Number: 002 • 2023 Pediatric Rheumatology Symposium

    Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

    Coziana Ciurtin1, Junjie Peng1, Pierre Donnes1, Stacy Ardoin2, Laura Schanberg3, Laura Lewandowski4, George A Robinson1 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2Nationwide Children's Hospital, Columbus, OH, 3Duke University Medical Center, Durham, NC, 4NIAMS, NIH, Bethesda, MD

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of…
  • Abstract Number: 0649 • ACR Convergence 2022

    Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity

    Marc Scherlinger1, Wenliang Pan2, Ryo Hisada1, Milena Vukelic3, Masataka Umeda1, Afroditi Boulougoura2, Maria Tsokos1 and George Tsokos2, 1BIDMC Harvard University, Boston, MA, 2Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
  • Abstract Number: 0660 • ACR Convergence 2022

    Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study

    Audrey Hagiwara1, Moumita Bose1, Aleksandr Stotland1, Aleksandra Binek1, Koen Raedschelders1, Janet Wei1, C. Noel Bairey Merz1, Sarah Parker1, Jennifer Van Eyk1, Daniel Wallace1, Mariko Ishimori2 and Caroline Jefferies1, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Health System, Los Angeles, CA

    Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
  • Abstract Number: 0690 • ACR Convergence 2022

    The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis

    Ajay Tambralli1, Alyssa Harbaugh1, Christine Rysenga1, Kaitlyn Sabb1, Srilakshmi Yalavarthi1, Claire Hoy1, Yu (Ray) Zuo1 and Jason S Knight2, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
  • Abstract Number: 1157 • ACR Convergence 2022

    Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity

    Brenda Seymour1, Brandon Trent2, Brendan Allen3, Adam Berlinberg1 and Kristi Kuhn3, 1University of Colorado Anschutz Medical Campus, Denver, CO, 2University of Colorado Anschutz Medical Campus, Eugene, OR, 3University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: While intestinal dysbiosis and the Th17 pathway are linked to the pathophysiology of spondyloarthritis (SpA), the mechanisms by which this occurs are unknown. We…
  • Abstract Number: 1415 • ACR Convergence 2022

    Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study

    Mona Alotaibi1, Roxana Coras2, Dimitrios Pappas3, Ted Mikuls4, Joel Kremer5, Geoffrey Thiele6, mohit jain1 and Monica Guma7, 1Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, 2University of California San Diego, San Diego, CA, 3CorEvitas, LLC, Waltham, MA, 4Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5The Corrona Research Foundation, Delray Beach, FL, 6University of Nebraska Medical Center, Omaha, NE, 7UCSD, La Jolla, CA

    Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…
  • Abstract Number: 1416 • ACR Convergence 2022

    Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study

    Roxana Coras1, Mona Alotaibi2, Dimitrios Pappas3, Joel Kremer4, Jeffrey Curtis5, Arthur Kavanaugh6, Ted Mikuls7, Geoffrey Thiele8, mohit jain2 and Monica Guma9, 1University of California San Diego, San Diego, CA, 2Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5University of Alabama at Birmingham, Hoover, AL, 6University of California San Diego, La Jolla, CA, 7Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 8University of Nebraska Medical Center, Omaha, NE, 9UCSD, La Jolla, CA

    Background/Purpose: Bioactive lipids comprise distinct classes of bioactive molecules with functions that are critical for joint disease, including regulation of not only inflammation but also…
  • Abstract Number: 1500 • ACR Convergence 2022

    Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry

    John Koussiouris1, Nikita Looby2, Max Kotlyar3, Vathany Kulasingam4, Igor Jurisica5 and Vinod Chandran6, 1Department of Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute/ Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Department of Laboratory Medicine and Pathobiology, University of Toronto/ Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 5Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network/ Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada, 6Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Psoriasis is an inflammatory skin disease that affects over 7.25 million Americans and 1.25 million Canadians. Approximately 25% of psoriasis patients, have an inflammatory…
  • Abstract Number: 1611 • ACR Convergence 2022

    Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis

    Thierry Sornasse1, Liang Li2, Shuang Zhao2, Xiaohang Wang2, Fang Cai3, Yingtao Bi4, In-Ho Song5, Stephanie Wichuk6, Robert G. Lambert7 and Walter P Maksymowych8, 1AbbVie, South San Francisco, CA, 2The Metabolomics Innovation Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada, 3AbbVie, Redwood City, CA, 4AbbVie, Inc, Worcester, MA, 5AbbVie, Inc., North Chicago, IL, 6University of Alberta, Edmonton, AB, Canada, 7Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Upadacitinib (UPA) 15 mg QD is efficacious in patients with active ankylosing spondylitis (AS) exhibiting inadequate responses to nonsteroidal anti-inflammatory drugs (NSAIDs-IR).1 We determined…
  • Abstract Number: 1820 • ACR Convergence 2022

    Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls

    Blanka Stiburkova1, Kateřina Pavelcová1, Jana Bohatá1, Karel Pavelka2, Lenka Hasíková1, Jakub Závada1, Aleš Kvasnička3, Dana Dobešová3 and David Friedecký3, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 3Palacky University Olomouc, Olomouc, Czech Republic

    Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…
  • Abstract Number: 1895 • ACR Convergence 2022

    Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis

    Jessica Murillo Saich1, Roxana Coras2, Robert Meyer3, Nancy Lane4 and Monica Guma5, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, San Diego, CA, 3San Diego VA Healthcare Service, San Diego, CA, 4University of California Davis, Hillsborough, CA, 5UCSD, La Jolla, CA

    Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee…
  • Abstract Number: 1906 • ACR Convergence 2022

    Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis

    Roxana Coras1, Jessica Murillo Saich2, Michal Hose Sanchez3, Anne Quan3, Emily Gentry1, Pieter Dorrestein1, Nancy Lane4 and Monica Guma5, 1University of California San Diego, San Diego, CA, 2University of California San Diego, La Jolla, CA, 3VA San Diego Healthcare System, San Diego, CA, 4University of California Davis, Hillsborough, CA, 5Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA

    Background/Purpose: Increasing evidence indicates that low grade systemic and local inflammation contributes to osteoarthritis (OA) progression. Bioactive lipid mediators are signaling molecules involved in inflammatory…
  • Abstract Number: 1993 • ACR Convergence 2022

    Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention

    Esha Lal1, Marta Sala Climent2, francesca cedola2, Marta Fernandez-Bustamante3, Meritxell Agustín-Perez2, Maram Alharti2, Abha Singh4, Soo-In Choi2, Tania Rivera2, Katherine Nguyen4, Susan Lee2, Aaron Armando5, Tiffany Holt6, Oswald Quehenberger5, Shahrokh Golshan6, Roxana Coras7 and Monica Guma8, 1Department of Medicine, School of Medicine, University of California, San Diego, San Diego, 2Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, 3Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, 4University of California, San Diego, San Diego, CA, 5Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, 6Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, 7University of California San Diego, San Diego, CA, 8UCSD, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology